GlassScriptPhysician profile
Earl E Bain
NPI 1396970539
$361.10
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $94.66 · 2021: $39.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $83.64 | 2019-2021 | |
| Lilly USA, LLC | $56.25 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.99 | 2019-2020 | |
| Almirall LLC | $29.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.09 | 2019 | |
| Galderma Laboratories, L.P. | $25.63 | 2019 | |
| Vyne Pharmaceuticals INC. | $22.54 | 2020 | |
| Mayne Pharma Commercial LLC | $16.23 | 2019 | |
| Leo Pharma INC. | $14.75 | 2019 | |
| Ucb, INC. | $14.66 | 2019 | |
| Genzyme Corporation | $12.52 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $4.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.